11 February 2021>: Clinical Research
Effect of I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
Zhongying Rui CDEF , Ruixin Wu BCD , Wei Zheng ADG* , Xuan Wang BDF , Zhaowei Meng AF , Jian Tan AFDOI: 10.12659/MSM.929590
Med Sci Monit 2021; 27:e929590
Table 2 CBC data before and after 131I therapy according to the number of treatment cycles and cumulative dose.
Mean±SD | Before | After (treatment cycles) | After (cumulative dose) | |||||
---|---|---|---|---|---|---|---|---|
One cycle | Two cycles | Three cycles | Four cycles | ≤5550 | 5551–11100 | >11100 | ||
WBCs, 10/L | 6.24±1.63 | 5.89±1.55* | 5.87±1.42* | 6.14±1.75 | 6.13±1.06 | 5.90±1.55* | 5.95±1.47* | 5.99±1.41 |
RBCs, 10/L | 4.63±0.46 | 4.78±0.50* | 4.72±0.49* | 4.71±0.48* | 4.95±0.49* | 4.78±0.50* | 4.72±0.50* | 4.85±0.49* |
Hb, g/L | 137.07±17.53 | 141.86±54.64* | 139.56±16.72* | 138.84±16.25* | 143.06±16.85* | 139.68±19.17* | 147.78±101.71 | 141.33±17.06* |
PLTs, 10/L | 255.03±65.88 | 251.63±67.17* | 249.24±74.63* | 260.81±77.18 | 254.16±66.18 | 251.58±67.25 | 254.70±74.84 | 246.70±71.72* |
Neutrophils, 10/L | 4.03±3.78 | 3.93±3.73 | 3.79±1.18 | 4.06±1.48 | 3.91±0.71 | 3.93±3.73 | 3.83±1.20 | 3.97±1.17 |
Lymphocytes, 10/L | 2.04±1.40 | 1.82±1.16* | 1.66±0.58* | 1.63±0.63* | 1.73±0.57* | 1.82±1.16* | 1.69±0.61* | 1.57±0.52* |
Monocytes, 10/L | 0.33±0.43 | 0.33±0.47 | 0.27±0.09 | 0.30±0.11 | 0.32±0.09* | 0.33±0.47 | 0.28±0.10 | 0.29±0.10* |
Hb – hemoglobin; PLT – platelet; RBC – red blood cell; SD – standard deviation; WBC – white blood cell. * a Indicates an increase and b a decrease. |